Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$0.81 +3.7%	$0.76	$0.51 ▼ $2.08	$44.83M	-0.22	56,599 shs	46,117 shs
GOVX GeoVax Labs	$1.02 +4.4%	$1.26	$0.73 ▼ $11.18	$14.12M	3.7	599,092 shs	522,744 shs
MRSN Mersana Therapeutics	$0.38 +5.5%	$0.41	$0.26 ▼ $3.63	$47.83M	1.68	2.49 million shs	2.06 million shs
SKYE Skye Bioscience	$1.91 +4.9%	$1.53	$1.14 ▼ $13.51	$59.16M	1.88	350,373 shs	211,600 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	+3.71%	+8.72%	+19.12%	-17.35%	-39.55%
GOVX GeoVax Labs	+4.42%	+34.19%	-8.11%	-47.42%	-28.17%
MRSN Mersana Therapeutics	+5.47%	+17.41%	+1.13%	-40.40%	-86.95%
SKYE Skye Bioscience	+4.95%	+21.66%	+1.81%	-29.99%	-85.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	2.5779 of 5 stars	3.5	3.0	0.0	1.8	2.5	0.6
GOVX GeoVax Labs	2.5896 of 5 stars	3.6	2.0	0.0	2.0	1.7	1.3
MRSN Mersana Therapeutics	3.7601 of 5 stars	3.5	2.0	4.1	2.2	2.5	0.0
SKYE Skye Bioscience	1.3766 of 5 stars	3.5	1.0	0.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.00	Buy	$8.00	887.65% Upside
GOVX GeoVax Labs	3.29	Buy	$12.90	1,164.71% Upside
MRSN Mersana Therapeutics	3.00	Buy	$4.00	942.21% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	769.11% Upside

Current Analyst Ratings Breakdown

Latest GOVX, CNTB, MRSN, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/31/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/21/2025	SKYE Skye Bioscience	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
3/21/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/3/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00
2/28/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
2/27/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
2/6/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$24.12M	1.86	N/A	N/A	$1.83 per share	0.44
GOVX GeoVax Labs	$3.95M	3.57	N/A	N/A	$3.24 per share	0.31
MRSN Mersana Therapeutics	$40.50M	1.18	N/A	N/A	$0.31 per share	1.24
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.17) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$59.50M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	-$25.97M	-$5.67	N/A	N/A	N/A	N/A	-809.87%	-349.34%	5/13/2025 (Estimated)
MRSN Mersana Therapeutics	-$171.67M	-$0.56	N/A	N/A	N/A	-214.20%	-401.37%	-38.61%	5/8/2025 (Estimated)
SKYE Skye Bioscience	-$37.65M	-$0.72	N/A	N/A	N/A	N/A	-45.78%	-37.44%	N/A

Latest GOVX, CNTB, MRSN, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	GOVX GeoVax Labs	-$0.51	N/A	N/A	N/A	$1.75 million	N/A
5/8/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	N/A	N/A	N/A	$6.05 million	N/A
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million
3/20/2025	Q4 2024	SKYE Skye Bioscience	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A
3/3/2025	Q4 2024	MRSN Mersana Therapeutics	-$0.16	-$0.11	+$0.05	-$0.11	$7.71 million	$16.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	N/A	12.04	N/A
GOVX GeoVax Labs	N/A	4.17	4.17
MRSN Mersana Therapeutics	13.35	2.35	2.35
SKYE Skye Bioscience	N/A	14.19	14.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
GOVX GeoVax Labs	6.09%
MRSN Mersana Therapeutics	93.92%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
GOVX GeoVax Labs	5.70%
MRSN Mersana Therapeutics	11.80%
SKYE Skye Bioscience	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.35 million	42.77 million	Optionable
GOVX GeoVax Labs	10	13.84 million	8.90 million	Not Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.96 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.43 million	Optionable

GOVX, CNTB, MRSN, and SKYE Headlines

Recent News About These Companies

Skye Bioscience announces inducement grant under Nasdaq listing rule

April 28 at 4:21 AM | markets.businessinsider.com

Skye Bioscience Inc.

April 26 at 7:31 PM | barrons.com

Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan

April 25, 2025 | quiverquant.com

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 25, 2025 | globenewswire.com

William Blair Comments on Skye Bioscience Q1 Earnings

April 19, 2025 | americanbankingnews.com

Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $16.60

April 19, 2025 | americanbankingnews.com

Rx Rundown: Merck, the CDC, GSK and more

April 18, 2025 | mmm-online.com

William Blair Predicts Skye Bioscience Q2 Earnings

April 18, 2025 | marketbeat.com

Analysts Offer Predictions for Skye Bioscience Q2 Earnings

April 18, 2025 | americanbankingnews.com

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

April 16, 2025 | seekingalpha.com

Skye Bioscience announces new preclinical data for nimacimab

April 15, 2025 | markets.businessinsider.com

Skye Bioscience Stock Rises on Preclinical Data for Weight Loss Drug

April 15, 2025 | marketwatch.com

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

April 15, 2025 | benzinga.com

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

April 15, 2025 | globenewswire.com

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

April 14, 2025 | globenewswire.com

Why Skye Bioscience, Inc.’s (SKYE) Stock Is Down 12.88%

April 1, 2025 | aaii.com

Skye Bioscience promotes Tu Diep to COO post

March 25, 2025 | thepharmaletter.com

Earnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progress

March 22, 2025 | uk.investing.com

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript

March 22, 2025 | insidermonkey.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 22, 2025 | finanznachrichten.de

Skye Bioscience price target lowered to $14 from $18 at Craig-Hallum

March 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX, CNTB, MRSN, and SKYE Company Descriptions

Connect Biopharma NASDAQ:CNTB

$0.81 +0.03 (+3.71%)

Closing price 04/28/2025 03:59 PM Eastern

Extended Trading

$0.83 +0.02 (+2.96%)

As of 04/28/2025 07:19 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

GeoVax Labs NASDAQ:GOVX

$1.02 +0.04 (+4.42%)

As of 04/28/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Mersana Therapeutics NASDAQ:MRSN

$0.38 +0.02 (+5.47%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-0.99%)

As of 04/28/2025 07:44 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Skye Bioscience NASDAQ:SKYE

$1.91 +0.09 (+4.95%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$1.84 -0.06 (-3.40%)

As of 04/28/2025 07:56 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time